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Abstract
Background: Multiple familial trichoepithelioma type 1 (MFT1; MIM 601606), a rare monogenic skin disease with
autosomal dominant inheritance, is characterized by the development of multiple skin-colored papules on the
central area of the face, frequently occurring in the nasolabial area. The disease is associated with various
mutations in the cylindromatosis (CYLD; MIM 605018) gene that are also responsible for familial cylindromatosis
(FC) and Brooke-Spiegler syndrome (BSS).
Methods: Recently we have identified a Spanish MFT1 pedigree with two affected family members (father and
daughter). Direct sequencing of the CYLD gene revealed a worldwide recurrent heterozygous nonsense mutation
(c.2272C/T, p.R758X) in the patients.
Results: This mutation has already been detected in patients with all three clinical variants – BSS, FC and MFT1 – of the
CYLD-mutation spectrum. Haplotype analysis was performed for the Spanish patients with MFT1, Dutch patients with
FC and an Austrian patient with BSS, all of whom carry the same heterozygous nonsense p.R758X CYLD mutation.
Conclusions: Our results indicate that this position is a mutational hotspot on the gene and that patients carrying the
mutation exhibit high phenotypic diversity.
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Background
Multiple familial trichoepithelioma type 1 (MFT1; MIM
601606) is an autosomal dominant condition characterized
by numerous firm skin-colored papules that are trichoe-
pitheliomas (follicular tumors). The tumors grow slowly in
size and number throughout life, often producing signifi-
cant cosmetic disfigurement.
MFT1, familial cylindromatosis (FC; MIM 132700)
and Brooke-Spiegler syndrome (BSS, MIM 605041) have
been independently mapped to chromosome 16q12-q13
by several groups [1–3]. First, FC was mapped to this re-
gion in 1995 [1], and its candidate gene, the CYLD gene,
was identified in 2000 [3]. Later BSS was mapped to the
same region in 2000 [4]. In the mapped region, the same
causative gene was identified in 2002 [5]. Regarding
MFT1, the same causative gene was identified in 2003
[6]. These genetic investigations supported the previous
clinical hypothesis, that MFT1 and FC might be the con-
sequence of the dysfunction of the same gene, since their
clinical symptoms can occur in the same patient or in
different patients within the same family [7].
In the mapped region, the cylindromatosis (CYLD)
gene [NM_015247] was identified as the causative gene
responsible for the development of these three diseases [3].
The gene encodes an enzyme with deubiquitinase activity,
which is involved in the post-translational modification
of its target proteins and removes Lys63-linked ubiquitin
chains [8]. The protein interacts with and negatively
regulates the TRAF2, TRAF6, NEMO and BCL3 proteins,
affecting the NF-ĸB signaling pathway [8].
Here we report a Spanish MFT1 pedigree with an af-
fected father and daughter, in whom we have identified the
recurrent p.R758X CYLD mutation. Previously reported
cases carrying the same mutation are reviewed to compare
the reported clinical phenotypes and to determine the geo-
graphical distribution of the mutation. Moreover, haplotype
analysis of the Spanish patients with MFT1, as well as
Dutch patients with FC and an Austrian patient with BSS
was performed to investigate whether the same or different
mutational events are responsible for the development of
these cases.
Methods
Patients
The Spanish MFT1 pedigree of Hispanic origin reported
here was identified in the Levant region of Valencia,
Spain. The 62-year-old father exhibited skin lesions that
developed progressively on the central area of the face
since the age of 14. Physical examination revealed mul-
tiple skin-colored papules measuring a few millimeters
and coalescing to form plaques in both nasolabial folds
(Fig. 1a), on the forehead, above the eyebrows and, to a
lesser extent, on the ears, on the back of the head and
on the back. Histological examination of one of the lesions
from the right eyebrow revealed multiple basaloid cell ag-
gregates with small keratinized cystic spaces surrounded
Fig. 1 Skin symptoms, histology findings and pedigree of a Spanish family with multiple familial trichoepithelioma type 1. Two affected family
members were identified. a The father presented skin-colored papules in the periorbital region, nose, nasolabial folds and upper lip. b Histological
features of trichoepithelioma were islands of basaloid cells with peripheral palisading and small horny cysts (hematoxylin-eosin staining; original
magnification × 10). c The daughter presented similar but smaller and fewer lesions in the nasolabial fold. d The pedigree of the investigated family.
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by specific follicular stroma (Fig. 1b). These findings were
consistent with the diagnosis of trichoepithelioma (cribri-
form trichoblastoma). Subsequently several biopsies were
taken and all histological results supported the diagnosis
of trichoepithelioma. The patient has been followed for
24 years, during which time the lesions have increased
in number and size. Treatment consisted of block exci-
sion of multiple localized trichoepithelioma plaques in
the nasolabial fold. Other lesions were treated mainly
with electrocoagulation. The patient is currently receiving
CO2 laser treatment.
The patient’s only child, a 33-year-old daughter, has
lesions similar to those of her father but are fewer in
number (Fig. 1c). The lesions first appeared in both
nasolabial folds and, over time, began to appear on her
forehead, temples, ears and scalp. Trichoepithelioma
was confirmed with a biopsy of a lesion from the right
temple. The daughter has been treated with electro-
coagulation and cryotherapy, followed by 5 % imiquimod
cream. Trichoepitheliomas in the left nasolabial fold were
also treated with a single session of photodynamic therapy
which had to be discontinued after a few minutes due to
intense pain the area. A burn subsequently appeared in
the treated area and took weeks to heal. Trichoepithelio-
mas were resolved but new lesions subsequently appeared
in the same area. At present, the patient is receiving a
CO2 laser treatment and is exhibiting good tolerance and
acceptable aesthetic results. To date, no clinical or histo-
logical evidence for cylindromas or spiradenomas has
been observed in either the father or the daughter. No
other clinically affected member has been identified in this
pedigree (Fig. 1d).
The data for Dutch and Austrian patients is publically
available, and we did not take any samples from these
patients ourselves. The investigated Dutch patients were
previously reported by Van den Ouweland et al. [9].
Based on the development of cylindromas, these patients
were diagnosed with FC. Their detailed clinical description
is present in the report of Van den Ouweland et al. [9].
The investigated Austrian patient was previously reported
by Grossmann et al. [10]. Based on the development of
different skin appendage tumors, the diagnosis of BSS was
established. The detailed clinical description of the symp-
toms is available in the study of Grossmann et al. [10].
Genetic investigation
The enrollment of the Spanish patients into the genetic
investigations have been approved by the Clinical Re-
search Ethics Committee (CEIC) of Consorcio Hospital
General Universitario de Valencia. The performed gen-
etic investigation was approved by the Internal Review
Board of the University of Szeged, Szeged, Hungary.
Written informed consents have been obtained from all
the investigated subjects. The study was conducted ac-
cording to the Principles of the Declaration of Helsinki.
Blood samples for genetic analyses were taken from
the Spanish patients and from their clinically unaffected
family members, as well as from unrelated controls.
Genomic DNA was isolated with a BioRobot EZ1 DSP
Workstation (QIAGEN; Godollo, Hungary). The coding
regions of the CYLD gene and the flanking introns were
amplified and sequenced (primer sequences were obtained
from the UCSC Genome Browser, www.genome.ucsc.edu).
For haplotype analysis of the Spanish, Dutch and
Austrian patients, common polymorphisms (n = 33) were
genotyped from regions upstream (n = 20; rs199912760,
rs375106322, rs201860550, rs149502055, rs376795685,
rs144013604, rs75157714, rs201233994, rs200973965,
rs77528321, rs146702654, rs6145827, rs3064638,
rs73584492, rs190892314, rs200678983, rs76797023,
rs77678929, rs376799359, rs201103123) and downstream
(n = 13; rs370702435, rs10451132, rs201757487,
rs137990687, rs368656359, rs149201712, rs185111122,
rs146946436, rs141129479, rs72796392, rs111543527,
rs11866167, rs35072258) of the identified mutation. A
detailed list of the investigated polymorphisms is presented
in Table 1. Genotypes of the investigated polymorphisms
were determined with direct sequencing.
Results and discussion
Direct sequencing of the coding regions and the flanking
introns of the CYLD gene from the investigated Spanish
patients revealed a previously described nonsense mu-
tation in exon 17 (c.2272C/T, p.R758X, rs121908388).
This mutation results in a premature termination codon
causing truncation and, thus, dysfunction of the CYLD pro-
tein. Both patients carried the mutation in heterozygous
form (Fig. 2a), whereas the unaffected family members
and unrelated controls carried the wild-type sequence
(Fig. 2b, Additional file 1.). The identified mutation was
located in the ubiquitin-specific protease domain of the
CYLD protein (Fig. 2c).
Previously reported Dutch and Austrian cases carrying
the same mutation were also investigated in this study
[9, 10]. Haplotype analysis of the Spanish patients with
MFT1, the Dutch patients with FC and Austrian patients
with BSS was performed (Table 1.). Our results demon-
strated that the Spanish and the Dutch pedigrees carry
the same haplotype, whereas the Austrian patient carries
a different haplotype. Thus, it can be assumed that differ-
ent mutational events are responsible for the development
of the Austrian case and the Spanish and Dutch cases.
A review of all previous studies reporting the same
c.2272C/T, p.R758X nonsense mutation of the CYLD
gene revealed that this mutation has also been detected
in patients with BSS [10–12], FC [3, 9, 13] and MFT1
[10, 14]. Thus, the c.2272C/T, p.R758X nonsense mutation
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of the CYLD gene can lead to the manifestation of any of
the clinical variants in the disease spectrum caused by
CYLD mutation, which is associated with high phenotypic
diversity. Furthermore, this mutation has been detected in
Caucasian American [3], South African [10], Austrian
[10, 14], Czech [11], Dutch [9], Chinese [12] and Japanese
patients [13] and is, thus, considered a recurrent world-
wide mutation (Table 2.). These data suggest that the
c.2272C/T, p.R758X nonsense mutation is located at a
mutational hotspot in the CYLD gene.
Table 1 Haplotype analysis of Spanish, Dutch and Austrian patients carrying the same recurrent nonsense mutation
Nationality Spanish Dutch Austrian
II/1 II/2 III/1
Healthy Symptomatic Symptomatic Symptomatic Symptomatic Symptomatic
Polymorphism ID Frequent
allele
rs35072258 TC/- TCTC TCTC TCTC TCTC TCTC TCTC
rs11866167 C/A CC CC CC CC CC CC
rs111543527 T/C TT TT TT TT TT TT
rs72796392 T/C TT TT TT TT TT TT
rs141129479 A/G AA AA AA AA AA AA
rs146946436 A/G AA AA AA AA AA AA
rs185111122 T/C TT TT TT TT TT TT
rs149201712 AC/- ACAC ACAC ACAC ACAC ACAC ACAC
rs368656359 G/A GG GG GG GG GG GG
rs137990687 G/A GG GG GG GG GG GG
rs201757487 G/- GG GG GG GG GG GG
rs10451132 G/T GG GG GG GG GG GT
rs370702435 A/G AA AA AA AA AA AA
rs121908388 C/T CC CT CT CT CT CT
rs199912760 G/A GG GG GG GG GG GG
rs375106322 G/A GG GG GG GG GG GG
r201860550 G/T GG GG GG GG GG GG
rs149502055 C/T CC CC CC CC CC CC
rs376795685 G/A GG GG GG GG GG GG
rs144013604 A/G AA AA AA AA AA AA
rs75157714 G/A GG GG GG GG GG GG
rs201233994 AT/- AT AT AT AT AT AT
rs200973965 ATAC/- ATAC ATAC ATAC ATAC ATAC ATAC
rs77528321 T/C TT TT TT TT TT TT
rs146702654 T/- TT TT TT TT TT TT
rs6145827 ACACAC/- ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
rs3064638 ACACAC/- ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
- -
rs73584492 A/G AA AA AA AA AA AA
rs190892314 A/G AA AA AA AA AA AA
rs200678983 C/T CC CC CC CC CC CC
rs76797023 A/T AA AA AA AA AA AA
rs77678929 T/A TT TT TT TT TT TT
rs376799359 A/T AA AA AA AA AA AA
rs201103123 C/T CC CC CC CC CC CC
Farkas et al. BMC Genetics  (2016) 17:36 Page 4 of 6
To determine whether the worldwide recurrent p.R758X
mutation of the CYLD gene is the result of one or more
independent mutational events, we performed haplo-
type analysis. The haplotype analysis of the Spanish,
Dutch and Austrian patients demonstrated that, al-
though the Spanish and the Dutch patients carry the
same haplotype, the clinical appearance, MFT1 and FC,
respectively, is different (Table 1.). These results sug-
gest the importance of modifying genetic and/or envir-
onmental factors. In contrast with these, the Austrian
patient carried a different haplotype than the Spanish
and Dutch families. Thus, we assume the presence of
the same mutation is the consequence of different mu-
tational events (Table 1.).
Conclusion
Our results support the conclusion that position 2272 in
the nucleotide sequence of the CYLD cDNA [NM_015247]
is a mutational hotspot on the CYLD gene. This result
correlates well with our previous findings for Hungarian
and Anglo-Saxon BSS families carrying the same het-
erozygous nonsense mutation (c.2806C > T, p.Arg936X)
but different haplotypes [15]. Of note, both mutational
hotspots are the location of recurrent nonsense mutations.
Regarding the encoded functional domains, both of
mutational hotspots affect the ubiquitin-specific protease
domain of the CYLD protein (Fig. 2c). Both recurrent
nonsense mutations have been reported for all three clin-
ical variants (MFT1, BSS, FC) of the CYLD-mutation
based disease spectrum and have been associated with
high intra- and interfamilial phenotypic diversity [15].
These reports raise the question of how these two
worldwide recurrent nonsense mutations can lead to the
development of the different clinical variants of the
CYLD-mutation based disease spectrum. Further studies
are needed to identify putative genetic, environmental or
lifestyle factors and to elucidate the mechanism leading
to the enormous phenotypic differences observed in pa-
tients carrying the same c.2272C/T, p.R758X nonsense
mutation.
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Fig. 2 Direct sequencing of the CYLD gene. Direct sequencing revealed a nonsense mutation (c.2272C/T, p.R758X) in exon 17. a The affected
family members carried the deletion in heterozygous form. b The unaffected family members carried the wild-type sequence. c The mutation
is located in the region of the ubiquitin-specific protease domain of the CYLD protein
Table 2 Summary of the geographical location and clinical manifestation of the recurrent p.R758X CYLD mutation
CYLD cDNA CYLD protein Detected in patients with Nationality References
c.2272C > T p.R758X FC Caucasian American, Dutch, Japanese [3, 9, 13]
BSS Austrian, South African, Czech, Chinese [10–12]
MFT1 Austrian, Spanish [10, 14], present study
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Additional file
Additional file 1: Sequencing data of Patient III/1 demonstrated the
same heterozygous mutation, which has been detected in case of
Patient II/2. (JPG 163 kb)
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